Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary
  • PDF PDF

ACRIA Studies in Progress

Summer 2003


Standard of Care Treatment vs. ZEST Once-Daily Regimen

This trial will study whether people on their first HAART regimen who take their drugs two or more times a day can switch to a once-daily regimen. People in the trial will either remain on their current medications, or switch to Zerit XR, Epivir and Sustiva (ZEST) taken once daily. They will visit ACRIA 9 times over 11 months. All blood tests, study visits, and study medications (Zerit XR, Epivir & Sustiva), as well as medications from the Standard Of Care arm that are manufactured by the sponsor, will be provided at no charge to the participants. Prescriptions will be written for any other anti-HIV drug. You are eligible if you are HIV-positive, age 18 or over, and on an initial HAART regimen (one or more NRTIs, at least one agent must have a twice-daily dosing schedule, and no NNRTI in the past or in current regimen) with a viral load below 50. Study participants will be reimbursed $25 for each visit.


RESIST 1: Tipranavir in Multi-Drug Resistant Patients

Advertisement
This trial will study the safety and efficacy of tipranavir (a protease inhibitor) boosted with low-dose ritonavir in people who have taken multiple antiretrovirals. This study lasts about 11 months, with 10-12 visits to ACRIA. All blood tests, study visits, and study medications will be provided by the sponsor. All patients must have taken drugs from each of the three antiretroviral classes, have taken at least two protease inhibitors, have a viral load over 1,000, and must currently be taking a protease inhibitor. Patients who do not qualify will be screened for RESIST II, another trial of tipranavir. Participants will be reimbursed $25 for each visit.

For the above trials, contact Dr. Douglas Mendez at 212-924-3934 ext. 126 or Dr. Yuriy Akulov at 212-924-3934 ext. 124


Social Networks Study

We have completed the first phase of enrollment for this study. Results from this study will be available soon on our website. If you want to participate in future HIV Over 50 studies, contact Salone Howard at 212-924-3934 x105 or email showard@acria.org.


Using Complementary Treatments to Manage HIV/AIDS

People in this study will be interviewed and complete a brief survey about treatments other than antiretrovirals, such as supplements, exercise, acupuncture, herbal remedies, as well as who provides the treatments, how often they use them, and if they feel they are helpful. Participation will require approximately 90 minutes, and people receive $25 for their time. To qualify, people must be HIV+, using HAART for at least a year, and be using other treatments for HIV/AIDS. To enroll, call Philana Rowell at 212-924-3934 x125 or email prowell@acria.org.


HIV Over 50 Database

ACRIA is currently establishing a large cohort to conduct research on HIV+ people over 50. If you would like to be included in this database, please contact Salone Howard at 212-924-3934 x105 or email showard@acria.org.


Web Research Study

This internet survey studies the extent to which HIV service providers may benefit from HIV prevention programs or programs designed to assist them in other areas of their job. Visit www.acria.org to participate.





  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary
  • PDF PDF

This article was provided by AIDS Community Research Initiative of America. It is a part of the publication ACRIA Update. Visit ACRIA's website to find out more about their activities, publications and services.
 

Tools
 

Advertisement